Annals of Surgical Oncology

, Volume 18, Issue 13, pp 3615–3622 | Cite as

Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial

  • Matthew H. G. Katz
  • Robert Wolff
  • Christopher H. Crane
  • Gauri Varadhachary
  • Milind Javle
  • E. Lin
  • Douglas B. Evans
  • Jeffrey E. Lee
  • Jason B. Fleming
  • Peter W. T. Pisters
Pancreatic Tumors

Abstract

Purpose

We conducted a phase II trial to assess the survival duration and quality of life of patients who received adjuvant interferon-based chemoradiation for pancreatic adenocarcinoma after pancreaticoduodenectomy.

Methods

Patients with a performance status of 0 or 1 were enrolled to receive interferon-alfa-2b (3 million units MWF), cisplatin (30 mg/m2, 6 doses) and 5-fluorouracil (5-FU; 175 mg/m2/day), concurrent with external-beam radiation (50.4 Gy) and followed by 2 courses of systemic 5-FU. The protocol was modified to include an optional 9 day break in the middle of chemoradiation. Quality of life was assessed by use of validated instruments.

Results

Twenty-eight patients were eligible for analysis. The operation of 15 (54%) patients was performed at other institutions. All patients had T3 tumors, 22 (79%) had positive lymph nodes and 4 (14%) had positive (R1) margins. 24 (86%) patients completed therapy. In all, 25 (89%) patients experienced grade 3 toxicity and 3 (11%) patients were hospitalized. The most common grade 3 events were leukopenia (15, 54%) and neutropenia (12, 43%). No grade 4 toxicity occurred. Overall quality of life decreased during chemoradiation but returned to baseline thereafter and was stable throughout surveillance. 19 patients have died; the median follow-up of the 9 survivors is 62 months. The median OS duration of treated patients was 42.3 (95% confidence interval 30.5–54.2) months.

Conclusions

Adjuvant interferon-based chemoradiation can be delivered safely and tolerably—though with substantial reversible toxicity—to patients of good performance status at an experienced cancer center. Therapy may be associated with an improvement in overall survival.

Supplementary material

10434_2011_1847_MOESM1_ESM.eps (739 kb)
Supplementary Fig. 1b Treatment scheme after institution of an optional 9-day treatment break in the middle of chemoradiation (EPS 739 kb)
10434_2011_1847_MOESM2_ESM.eps (729 kb)
Supplementary Fig. 2b Kaplan–Meier survival curve for disease-free survival (DFS) (EPS 729 kb)
10434_2011_1847_MOESM3_ESM.eps (757 kb)
Supplementary Fig. 3c Responses over time to specific questions in the QOL surveys. c “To what extent have you been troubled by side effects from your treatment over past week?” (Quality of Life Questionnaire-Pancreas 26). Responses were converted to a discrete numerical scale; points represent mean (bars represent SD) of all patients’ responses to the query at each time point. Mid CXRT midpoint of chemoradiation, Post CXRT after chemoradiation, Pre CTX1 before chemotherapy cycle 1; Pre CTX 2 before chemotherapy cycle 2. Numbers refer to months after completion of therapy (EPS 758 kb)
10434_2011_1847_MOESM4_ESM.eps (756 kb)
Supplementary Fig. 3d Responses over time to specific questions in the QOL surveys. d “How many times have you felt sad over past week?” (Center for Epidemiologic Studies-Depression). Responses were converted to a discrete numerical scale; points represent mean (bars represent SD) of all patients’ responses to the query at each time point. Mid CXRT midpoint of chemoradiation, Post CXRT after chemoradiation, Pre CTX1 before chemotherapy cycle 1; Pre CTX 2 before chemotherapy cycle 2. Numbers refer to months after completion of therapy (EPS 757 kb)

References

  1. 1.
    Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.Google Scholar
  2. 2.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 1999;230:776–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.PubMedCrossRefGoogle Scholar
  4. 4.
    Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2000;179:367–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Ismail A, Van Groeningen CJ, Hardcastle A, et al. Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma. Mol Pharmacol. 1998;53:252–61.PubMedGoogle Scholar
  8. 8.
    Vokes EE. The promise of biochemical modulation in combined modality therapy. Semin Oncol. 1994;21:29–33.PubMedGoogle Scholar
  9. 9.
    Wadler S, Wersto R, Weinberg V, et al. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res. 1990;50:5735–9.PubMedGoogle Scholar
  10. 10.
    Byfield JE, Calabro-Jones P, Klisak I, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or FTORAFUR and X rays. Int J Radiat Oncol Biol Phys. 1982;8:1923–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Holsti LR, Mattson K, Niiranen A, et al. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1987;13:1161–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Picozzi VJ, Abrams RA, Decker PA, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG trial Z05031. Ann Oncol. 2011;22:348–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Marten A, Schmidt J, Debus J, et al. CapRI: final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-a2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). J Clin Oncol. 2010;28(Suppl):LBA4012.Google Scholar
  14. 14.
    Linehan DC, Tan MC, Strasberg SM, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg. 2008;248:145–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Common terminology criteria for adverse events (CTCAE), version 3. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2003.Google Scholar
  16. 16.
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Hjermstad MJ, Fossa SD, Bjordal K, et al. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol. 1995;13:1249–54.PubMedGoogle Scholar
  18. 18.
    Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer. 1999;35:939–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Radloff L. A new self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRefGoogle Scholar
  20. 20.
    Hwang RF, Wang H, Lara A, et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008;15:1356–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Katz MH, Merchant NB, Brower S, et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18:337–44.PubMedCrossRefGoogle Scholar
  22. 22.
    Aloia TA, Lee JE, Vauthey JN, et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007;204:347–55.PubMedCrossRefGoogle Scholar
  23. 23.
    Posner MC, Gooding WE, Landreneau RJ, et al. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am. 1998;4:237–46.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Matthew H. G. Katz
    • 1
  • Robert Wolff
    • 2
  • Christopher H. Crane
    • 3
  • Gauri Varadhachary
    • 2
  • Milind Javle
    • 2
  • E. Lin
    • 4
  • Douglas B. Evans
    • 5
  • Jeffrey E. Lee
    • 1
  • Jason B. Fleming
    • 1
  • Peter W. T. Pisters
    • 1
  1. 1.Department of Surgical OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Gastrointestinal Medical OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Radiation OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  4. 4.Department of BiostatisticsThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  5. 5.Department of SurgeryThe Medical College of WisconsinMilwaukeeUSA

Personalised recommendations